Urologist Practice Structure and Spending for Prostate Cancer Care.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 26 11 2018
revised: 19 02 2019
accepted: 08 03 2019
pubmed: 29 4 2019
medline: 16 1 2020
entrez: 29 4 2019
Statut: ppublish

Résumé

To investigate the impact of urologist practice structure on health care spending for men with prostate cancer. We hypothesize that 3 elements of urologist practice structure may influence spending for prostate cancer care: urologist participation within a multispecialty group (MSG), practice size among single specialty urology groups, and intensity-modulated radiation therapy (IMRT) ownership. We used a 20% sample of fee-for-service Medicare beneficiaries to identify men newly diagnosed with prostate cancer between 2011 and 2014. We identified each man's urologist and used data from the Healthcare Relational Spheres provider files to identify practice type, size, and IMRT ownership for each urologist. We then fit generalized linear mixed models to estimate the association between these practice features and Medicare payments in the year after diagnosis. All models were adjusted for patient and healthcare market characteristics. We identified 35,929 men with newly diagnosed prostate cancer who were treated by 6381 urologists. Medicare payments for men with newly diagnosed prostate cancer were significantly lower in MSGs ($19,181 v. $22,366 large single specialty group, P < 0.001) and significantly higher among practices with IMRT ownership ($23,801 v. $20,162 for non-owners, P < 0.001). These differences persisted in sensitivity analyses including only men treated with radiotherapy and examining only prostate cancer-related claims. Urologist practice structure is associated with payments for prostate cancer care. MSGs had the lowest Medicare payments per episode of prostate cancer care while groups with IMRT ownership had the highest.

Identifiants

pubmed: 31029672
pii: S0090-4295(19)30372-3
doi: 10.1016/j.urology.2019.03.029
pmc: PMC6660353
mid: NIHMS1021270
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

65-71

Subventions

Organisme : AHRQ HHS
ID : R01 HS025707
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA180984
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Références

J Clin Epidemiol. 2000 Dec;53(12):1258-67
pubmed: 11146273
N Engl J Med. 2001 Jul 12;345(2):99-106
pubmed: 11450679
Health Aff (Millwood). 2004 Mar-Apr;23(2):70-81
pubmed: 15046132
Health Aff (Millwood). 2004 Mar-Apr;23(2):82-90
pubmed: 15046133
J Clin Oncol. 2005 Nov 1;23(31):7881-8
pubmed: 16204005
J Natl Cancer Inst. 2006 Jun 21;98(12):839-45
pubmed: 16788157
J Urol. 2007 Jun;177(6):2106-31
pubmed: 17509297
Urol Clin North Am. 2009 Feb;36(1):95-100, vii
pubmed: 19038641
Health Aff (Millwood). 2009 Mar-Apr;28(2):w358-67
pubmed: 19240056
JAMA. 2009 Dec 9;302(22):2444-50
pubmed: 19996399
Health Aff (Millwood). 2010 Mar-Apr;29(3):537-43
pubmed: 20110290
J Clin Oncol. 2010 Mar 1;28(7):1117-23
pubmed: 20124165
Health Aff (Millwood). 2010 May;29(5):991-7
pubmed: 20439896
J Urol. 2010 Dec;184(6):2480-4
pubmed: 20952030
N Engl J Med. 2010 Nov 4;363(19):1822-32
pubmed: 21047226
N Engl J Med. 2010 Dec 23;363(26):2477-81
pubmed: 21142528
J Natl Cancer Inst. 2011 Jan 19;103(2):117-28
pubmed: 21228314
Health Aff (Millwood). 2011 Aug;30(8):1575-84
pubmed: 21719447
J Urol. 2013 Jul;190(1):97-101
pubmed: 23399652
Am J Manag Care. 2013 May 01;19(5):e175-84
pubmed: 23781916
N Engl J Med. 2013 Oct 24;369(17):1629-37
pubmed: 24152262
Health Aff (Millwood). 2014 Jun;33(6):972-9
pubmed: 24889946
JAMA Surg. 2016 Jan;151(1):5-6
pubmed: 26509237
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
JAMA Intern Med. 2016 Mar;176(3):412
pubmed: 26954048
JAMA. 2016 Jun 14;315(22):2397-8
pubmed: 27213914
Am J Manag Care. 2016 Sep;22(9):569-75
pubmed: 27662220
Eur Urol. 2018 Apr;73(4):491-498
pubmed: 28823605
Ann Intern Med. 1996 Mar 15;124(6):577-84
pubmed: 8597322

Auteurs

Parth K Modi (PK)

Dow Division for Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI.

Lindsey A Herrel (LA)

Dow Division for Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI.

Samuel R Kaufman (SR)

Dow Division for Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI.

Phyllis Yan (P)

Dow Division for Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI.

Tudor Borza (T)

Dow Division for Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI.

Ted A Skolarus (TA)

Dow Division for Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI.

Florian R Schroeck (FR)

Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth College, Hanover, NH.

Brent K Hollenbeck (BK)

Dow Division for Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI.

Vahakn B Shahinian (VB)

Department of Internal Medicine, University of Michigan, Ann Arbor, MI. Electronic address: vahakn@umich.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH